Relay Therapeutics, Inc.
RLAY
Rang în acțiuni
#4221
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Preț acțiune
$17.16
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$3.76B
Schimbare (1 zi)
5.41%
Schimbare (1 an)
140.34%
Țară
US
Tranzacționează Relay Therapeutics, Inc. (RLAY)
Categorie
Healthcare
Câștiguri pentru Relay Therapeutics, Inc. (RLAY)
Câștiguri în Jun 2026 TTM: $-286.04M
Conform celor mai recente rapoarte financiare ale Relay Therapeutics, Inc., câștigurile actuale ale companiei sunt $-286.04M. În anul 2023, compania a înregistrat un câștig de $-341.97M, o scădere comparativ cu câștigului din 2022, care a fost de $-290.51M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Relay Therapeutics, Inc. din 2018 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $-286.04M | -15.30% |
| 2024 | $-337.71M | -1.25% |
| 2023 | $-341.97M | 17.72% |
| 2022 | $-290.51M | -20.16% |
| 2021 | $-363.87M | 594.25% |
| 2020 | $-52.41M | -30.40% |
| 2019 | $-75.31M | 54.36% |
| 2018 | $-48.79M | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | -1,944.13% |
US
|
|
| $-3.09B | 979.23% |
US
|
|
| $-4.02B | 1,304.08% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -781.96% |
NL
|
